Table 1.
Characteristics of the patients included in the study.
Fig 1.
Controlled attenuation parameter before (CAP) and after adaptation (CAPa) of measurement depth in the group of patients with probe-to-capsula distance (PCD) >35 mm.
Notched box plots showing CAP and CAPa. The line in the box indicates the median; the height of each box is the median ± (1.57 interquartile range/√n), used to assess the 95% confidence interval around group medians. Differences are considered to be significant if the shaded boxes do not overlap (p< 0.05). The horizontal lines above and below each box indicate the interquartile range (from the 25th to the 75th percentile), and the vertical lines at the ends of the box encompass the adjacent values (upper: 75th percentile + 1.5 times the interquartile range; lower: 25th percentile—1.5 times the interquartile range).
Table 2.
Characteristics of the patients with probe-to capsula distance (PCD) <35 mm versus >35 mm.
Fig 2.
Distribution of appropriate controlled attenuation parameter (CAPa) according to steatosis stage.
Notched box plots showing the relationship between steatosis stage and CAPa. The line in the box indicates the median; the height of each box is the median ± (1.57 interquartile range/√n), used to assess the 95% confidence interval around group medians. Differences are considered to be significant if the shaded boxes do not overlap (p< 0.05). The horizontal lines above and below each box indicate the interquartile range (from the 25th to the 75th percentile), and the vertical lines at the ends of the box encompass the adjacent values (upper: 75th percentile + 1.5 times the interquartile range; lower: 25th percentile—1.5 times the interquartile range).
Fig 3.
ROC curves of appropriate controlled attenuated parameter (CAPa) for the detection of (A) steatosis (S≥1), moderate to severe steatosis (S≥2) and severe steatosis (S = 3).
The diagonal line represents detection achieved by chance alone (AUROC = 0.50); the ideal AUROC is 1.00.
Table 3.
Diagnostic performance of appropriate controlled attenuation parameter (CAPa) for the detection of steatosis stage.